Brief: Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million
06/08/2026 21:06
BRIEF-Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million Aug 06 (Reuters) - Lyell Immunopharma Q2 operating income USD -47.337 million.
- Q2 adjusted net income USD -40.622 million vs. IBES estimate USD -46.3 million
- Q2 revenue USD 4 thousand vs. IBES estimate USD 3.8 thousand
Recent news on Lyell Immunopharma
See all newsBrief: Lyell Immunopharma Says Additional Clinical Data And End-Of-Phase 1 FDA Meeting Expected In 2027
Lyell Immunopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a share - Earnings Preview
Brief: Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million
Brief: Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma